Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia-Reference-Cited by-同舟云学术

Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia

Published:2022-01 Issue:1 Volume:52 Page:49-56
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Body Amy¹^ORCID,Wong Rachel¹²³^ORCID,Shapiro Jeremy⁴,Jalali Azim³⁵,McLachlan Sue‐Anne⁶⁷,Ananda Sumitra³⁷⁸⁹,Lipton Lara⁴⁵⁹,Cooray Prasad⁷¹⁰,Gibbs Peter³⁵⁷,Lee Belinda³⁷⁹¹¹,Lee Margaret¹²³⁵

Affiliation:

1. Department of Medical Oncology Eastern Health Melbourne Victoria Australia

2. Monash University Eastern Health Clinical School Melbourne Victoria Australia

3. Walter and Eliza Hall Institute of Medical Research Melbourne Victoria Australia

4. Department of Medical Oncology Cabrini Hospital Melbourne Victoria Australia

5. Department of Medical Oncology Western Health Melbourne Victoria Australia

6. Department of Medical Oncology St Vincent's Hospital Melbourne Victoria Australia

7. Faculty of Medicine and Health Sciences University of Melbourne Melbourne Victoria Australia

8. Department of Medical Oncology Epworth Freemasons' Hospital Melbourne Victoria Australia

9. Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Victoria Australia

10. Department of Medical Oncology Knox Private Hospital Melbourne Victoria Australia

11. Department of Medical Oncology Northern Health Melbourne Victoria Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.15094

Reference27 articles.

1. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

4. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

5. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids;Cancers;2021-10-04

2. Pancreatic ductal adenocarcinoma survival in South Australia: time trends and impact of tumour location;ANZ Journal of Surgery;2021-04-06